Long-term use of anti-inflammatory drugs and risk of atrial fibrillation

Archives of Internal Medicine

Volumn 170, Issue 16, 2010, Pages 1450-1455

  De Caterina, Raffaele ^a   Ruigómez, Ana ^b   Rodríguez, Luís Alberto García ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACEMETACIN; ANTIINFLAMMATORY AGENT; AZAPROPAZONE; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; DICLOFENAC; ETODOLAC; FENBUFEN; FENOPROFEN; FLURBIPROFEN; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE; SULINDAC; TENOXICAM; TIAPROFENIC ACID;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; UNITED KINGDOM; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; MIDDLE AGED; RISK; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL FIBRILLATION; CASE-CONTROL STUDIES; FEMALE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK; RISK FACTORS;

EID: 77956976489     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.305     Document Type: Article

References (48)

1. Ostrander LD Jr, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation. 1965;31:888-898.
2. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet. 1987;1(8532):526-529.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
4. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74(3):236-241.
5. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14(6):666-672.
6. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J. 1996;131(4):790-795.
7. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol. 2003;42(1):93-100.
8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457.
9. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-364.
10. Guiraudon C, Ernst N, Yee R, Lein G. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients. In: Kingma J, Van Hernel N, Lie K, eds. Atrial Fibrillation: A Treatable Disease? Dordrecht, the Netherlands: Kluwer Academic Publishers; 1992:41-57.
11. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54(2):230-246.
12. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180-1184.
13. Bharti S, Lev M. Histology of the normal diseased atrium. In: Fall R, Podrid P, eds. Atrial Fibrillation: Mechanism and Management. New York, NY: Raven Press; 1992:15-39.
14. Pokharel S, van Geel PP, Sharma UC, et al. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation. 2004;110(19):3129-3135.
15. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103 (1):253-258.
16. Maixent JM, Paganelli F, Scaglione J, Lévy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9(6):612-617.
17. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766-768.
18. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686-689.
19. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57-64.
20. Ruigómez A, Johansson S, Wallander MA, García Rodríguez LA. Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation. BMC Cardiovasc Disord. 2002;2:5.
21. Ruigómez A, Johansson S, Wallander MA, García Rodríguez LA. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Disord. 2005;5:20.
22. Ruigómez A, Johansson S, Wallander MA, Rodríguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002;55(4):358-363.
23. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. J Am Coll Cardiol. 2004;44(11):2117-2124.
24. Ueda N, Yoshikawa T, Chihara M, Kawaguchi S, Niinomi Y, Yasaki T. Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol. 1988;2(1):29-31.
25. Fujimoto S, Kondoh H, Yamamoto Y, Hisanaga S, Tanaka K. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol. 1990;10(3):231-236.
26. Chikanza C, Fernandes L. Arrhythmia after pulse methylprednisolone therapy. Br J Rheumatol. 1991;30(5):392-393.
27. McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest. 1993;104(2):622-623.
28. Moretti R, Torre P, Antonello RM, Zorzon M, Cazzato G. Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment. Eur J Neurol. 2000;7(1):130.
29. Aslam AK, Vasavada BC, Sacchi TJ, Khan IA. Atrial fibrillation associated with systemic lupus erythematosus and use of methylprednisolone. Am J Ther. 2001;8(4):303-305.
30. Bocanegra TS, Castañeda MO, Espinoza LR, Vasey FB, Germain BF. Sudden death after methylprednisolone pulse therapy. Ann Intern Med. 1981;95(1):122.
31. Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med. 1981;95(6):781-782.
32. Thompson JF, Chalmers DH, Wood RF, Kirkham SR, Morris PJ. Sudden death following high-dose intravenous methylprednisolone. Transplantation. 1983;36(5):594-596.
33. Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005;16(3):360-366.
34. van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166(9):1016-1020.
35. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7(4):403-422.
36. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
37. Freedman MD, Schocket AL, Chapel N, Gerber JG. Anaphylaxis after intravenous methylprednisolone administration. JAMA. 1981;245(6):607-608.
38. Ozen S, Tokgozoglu L, Saatci U. Are late potentials operative in arrhythmias following methylprednisolone pulse therapy. Int J Cardiol. 1992;36(2):234-235.
39. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113(16):1950-1957.
40. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578-1587.
41. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-2913.
42. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068-2073.
43. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal antiinflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628-1636.
44. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2(11):879-890.
45. Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J Cardiovasc Pharmacol. 2008;52(1):4-10.
46. Gillis AM. Angiotensin-receptor blockers for prevention of atrial fibrillation - a matter of timing or target? N Engl J Med. 2009;360(16):1669- 1671.
47. Takayama K, Yuhki K, Ono K, et al. Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med. 2005;11(5):562-566.
48. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.